Your first 90 days
Your first 90 days on Zilbrysq for generalized myasthenia gravis
What happens before the first fill, the days that matter, the label's rules and who to call, from the label, the drugmaker's own program and one insurer's written rules.
Zilbrysq is a shot you or a caregiver give at home every day, and the first one waits on vaccines, not a pharmacy counter. The label requires meningitis vaccines at least 2 weeks before day 1, a pancreas blood test and a neurologist enrolled in a safety program. After that the routine is one injection a day, a card in your wallet and a fever rule that never relaxes. This page lays out the first 3 months from the FDA label, the REMS, UCB's ONWARD program and one insurer's written rules.
What has to happen before the first bottle ships
Zilbrysq is under a REMS, so the first shipment waits on meningitis vaccines, a certified neurologist, a pancreas blood test and insurance approval. These are the 9 things in the way, in order.
Meningitis vaccines, at least 2 weeks before the first dose
The label requires meningococcal vaccination against serogroups A, C, W, Y and B at least 2 weeks before day 1.
- It follows the ACIP schedule for people on a complement inhibitor, which differs from the usual schedule.
- Shots you had before may not be enough, and the neurologist decides whether you need more.FDA label
Or antibiotics, if treatment cannot wait
If you are not up to date and Zilbrysq must start right away, the label says to give antibiotics and vaccines as soon as possible.
- The Medication Guide says to take the antibiotics for as long as your healthcare provider tells you.
- The REMS requires the prescriber to write that antibiotic prescription.FDA label
A pneumonia vaccine as well
The label says Zilbrysq also raises the risk of infection from Streptococcus pneumoniae and Haemophilus influenzae.
- It asks prescribers to give pneumococcal vaccines on the ACIP schedule.
- Gonorrhea is a lesser risk, and the label asks prescribers to discuss prevention and regular testing with anyone at risk.FDA label
No active infection when you start
The Medication Guide asks you to tell your provider before starting if you have an infection or fever.
- The label also urges caution with any other infection, and Zilbrysq cannot be started during an unresolved serious meningococcal infection.FDA label
A pancreas blood test
Before the first dose, the label asks for baseline lipase and amylase levels.
- Pancreatitis and pancreatic cysts have been reported with Zilbrysq, and these 2 enzymes are how the neurologist checks the pancreas.FDA label
A certified neurologist, the Patient Guide and the Safety Card
Your neurologist must be enrolled in the ZILBRYSQ REMS before prescribing Zilbrysq.
- Before treatment they counsel you on meningococcal infection, give you the Patient Guide and Patient Safety Card, and check your vaccines.
- The FDA's REMS page lists enrollment forms for prescribers and pharmacies, but none for patients.FDA REMS page
One specialty pharmacy, PANTHERx Rare
UCB says one specialty pharmacy, PANTHERx Rare, dispenses Zilbrysq and signs you up automatically once it is prescribed.
- PANTHERx may contact your healthcare provider to document your vaccination history.
- It can also help you get the required shots at a local pharmacy or with an in-home option.Vaccination requirements
ONWARD, UCB's support program
Once the office sends the Start Form, ONWARD enrolls you and a Care Coordinator calls to welcome you.
- A ZILBRYSQ Welcome Kit comes with the first shipment from PANTHERx Rare.
- Coordinators can also schedule a refresher call on how to give the injection.ONWARD treatment prep
The insurance approval
PANTHERx Rare checks your benefits and works with your neurologist's office on any prior authorization.
- UCB shows these steps as an example and says coverage is not guaranteed.ONWARD insurance steps
The days that matter
Counted from the first injection, with the vaccine deadline 2 weeks before it, a refill every 28 days and the Safety Card's 2 extra months. Type your first-dose date and the tiles become real dates you can add to your calendar.
The tiles below count days from a first dose. Enter the date of yours, or the date you expect, and each tile becomes a real date on your calendar.
The date stays on your device. It is not sent to Trial Friend or anyone else. The calendar file works with Apple, Google and Outlook calendars.Start Form, REMS check and vaccine plan
The office sends the Start Form with your weight, antibody test, myasthenia class and MG-ADL score.
- It also lists your past meningitis vaccines or a prescription for the missing ones.
- None of the sources on this page sets how long the approval takes.
Pancreas blood test
The label asks for lipase and amylase levels before the first dose.
- These give the neurologist a starting point if stomach pain or a raised enzyme shows up later.
Vaccine deadline
Meningococcal vaccines need to be completed or updated at least 2 weeks before day 1, by the label.
- If that cannot happen, the neurologist decides whether to start with antibiotics instead.
Approval, then the pharmacy's call
Once insurance approves, PANTHERx Rare calls about your share of the cost and to schedule delivery.
- UCB says to confirm the shipment details on that call to avoid delays.
First injection, then one every day
One prefilled syringe under the skin of the belly or front of the thigh, at about the same time each day.
- Let a refrigerated syringe warm for 30 to 45 minutes first.
- The Patient Safety Card goes in your wallet from today, as the label asks.
Four weeks in
Blood levels of Zilbrysq reach a steady state by about week 4, according to the label.
- Injection site reactions, upper respiratory infections and diarrhea were the most common side effects, each in at least 10% of people.
Refill, then every 28 days
Each pack holds 28 syringes in 4 cartons of 7, so one pack lasts 28 days.
- The next pack is due here, and every 28 days after that.
Refill, number 2
Halfway through the first approval
In the Cigna policy below, the first approval lasts 6 months.
- Renewal needs the neurologist to say you are still benefiting, such as better speech, swallowing, mobility or breathing.
Refill, number 3
The label, revision by revision
The FDA lists which sections changed in each revision of a label. These are the revisions the current Zilbrysq label records, dated by the FDA, with a plain note on what each one meant for a patient. Older references and handouts can lag these by months.
Label dated October 15, 2026, read on DailyMed. FDA label
- October 2026
A single-dose prefilled autoinjector was added at the same 3 doses, in packs of 28. The dose table no longer lists syringe plunger colors, and the Instructions for Use say to check the dose printed on the label.FDA letter
- January 2026
Contact details for the pregnancy exposure registry, through UCBCares, were added to the label and the Medication Guide.FDA letter
- February 2025
The boxed warning, vaccine and antibiotic instructions, the contraindication and the infection warnings were revised to match other complement inhibitors. The FDA approved a modified REMS in the same letter.FDA letter
- April 2024
Morphea, a patchy hardening of the skin, was added to the side effects reported after approval.FDA letter
How the label says to take it
The parts of the prescribing information and the patient leaflet that come up in the first 3 months, in plain words.
- One injection a day, dose by weight
The label sets 16.6mg for people under 56kg (about 123 lb) and 23mg from 56kg to under 77kg (about 123 to 170 lb).
- People at 77kg (about 170 lb) or more get 32.4mg, and each syringe holds one full dose.FDA label
- Training first, then at home
The label lets patients self-inject after training in injection technique.
- The Instructions for Use say not to inject until a healthcare provider has shown you how.FDA label
- Where to inject
Use the belly, at least 2 inches from the navel, or the front of the thighs, with a new spot each time.
- The back of the upper arm is only for when a caregiver gives the shot.
- The Instructions for Use say to avoid skin that is red, tender, bruised, swollen or hard, or has scars or stretch marks.FDA label
- If you miss a dose
The label says to inject the missed dose as soon as possible, then go back to the usual time.
- The label says never to inject more than 1 dose in a day.FDA label
- Storage
Keep syringes in the fridge at 36°F to 46°F (2°C to 8°C) in the original carton, never frozen.
- A carton can also stay at room temperature up to 86°F (30°C) for a single stretch of up to 3 months.
- Write the date on the carton, and never put it back in the fridge.FDA label
- Fever is a call, not a wait
The Medication Guide lists fever, headache with fever, a stiff neck, confusion and light hurting the eyes as signs of meningococcal infection.
- It says to call your provider or get emergency care right away.
- The Medication Guide says to show the Patient Safety Card to any provider who treats you.FDA label
- The card outlasts the drug
The label requires carrying the Patient Safety Card at all times during treatment and for 2 months after the last dose.
- The Medication Guide says the infection risk may continue for several weeks after stopping.FDA label
- Boosters
The label says to revaccinate on the ACIP schedule for as long as treatment lasts.
- Ask the neurologist when your next meningitis booster is due.FDA label
- Questions about the REMS
The Patient Guide gives the ZILBRYSQ REMS line, 1-877-414-8353, open Monday to Friday from 9 AM to 5 PM Eastern.
- It says only pharmacies in the REMS can fill the prescription and ship it to you.REMS Patient Guide
- Pregnancy and breastfeeding
There are no human data in pregnancy, and in monkeys zilucoplan raised the rate of fetal death at exposures similar to the human dose.
- It is not known whether it passes into breast milk.
- A pregnancy registry takes enrollments through UCBCares at 1-844-599-2273 or ucbcares@ucb.com, according to the label.FDA label
What the label says to act on
The symptoms the label singles out, and what it tells patients and prescribers to do about each. If any of these happen, the label's instruction is the one to follow, with your care team.
Signs of meningococcal infection
Fever, fever with a rash, fever with a fast heartbeat, headache with fever, headache with nausea or vomiting, or a stiff neck or back.
- Confusion, flu-like muscle aches and eyes sensitive to light count too.
- The Medication Guide says to call your provider or get emergency care right away, with the card in hand.FDA label
Other infections
The label says Zilbrysq also raises the risk of pneumococcal, Haemophilus and gonorrhea infections.
- In the main trial, upper respiratory infections occurred in 14% against 7% on placebo, and urinary infections in 8% against 5%.
- The Medication Guide says to call your provider right away about any new sign of infection.FDA label
Stomach pain that will not go away
Pain that lasts, is sometimes severe or spreads to the back, with or without vomiting, is the main sign of pancreatitis.
- The Medication Guide says to call your provider right away, and they will tell you whether to stop.
- In long-term studies, 1.9% had pancreatitis and 1.4% had pancreatic cysts.FDA label
Injection site reactions and diarrhea
In the 12-week trial, injection site reactions occurred in 29% on Zilbrysq against 16% on placebo, and diarrhea in 11% against 2%.
- The Medication Guide says to tell your provider about any side effect that bothers you or does not go away.FDA label
Patchy hardening of the skin
Morphea, a patchy hardening and discoloring of the skin, appeared in 5% of 213 patients in the long-term studies.
- Most cases began more than a year after starting and were mild to moderate, according to the label.FDA label
Why the pharmacy or the insurer says no, and what fixes it
Most first-fill delays are one of these. Knowing which one tells you who to call.
- The pharmacy cannot document your vaccinesThe REMS requires the pharmacy to check your vaccination status with the prescriber before the first shipment. If you were not up to date at the start, it keeps checking before each shipment for up to 6 months. The fix is the office sending vaccine dates or the antibiotic plan.FDA REMS page
- The shipment is on hold for vaccinesOn the Start Form's vaccine page, the neurologist chooses either to hold the shipment until missing vaccines are given or to dispense. A hold is a choice the office made, so ask them which box was checked.Start Form
- The prescription went to another pharmacyUCB says prescriptions are filled only through PANTHERx Rare, which takes calls at 833-418-7760. The office resends it there, so this is a routing problem, not a denial.Pharmacy flashcard
- Prior authorization pending or deniedPlans ask for criteria like those in the Cigna policy below, such as a positive AChR antibody test and earlier medicines. If a plan denies coverage, UCB says PANTHERx Rare works with your neurologist on an appeal, and you do not need to act.ONWARD insurance steps
- You are also on another myasthenia antibody or complement drugThe Cigna policy below does not cover Zilbrysq taken alongside another complement inhibitor, an FcRn blocker such as Vyvgart or Rystiggo, rituximab or Uplizna. Ask the neurologist how a switch from another of these drugs is planned.Cigna policy
- A copay you cannot payCommercial insurance may bring the cost to as little as $0. The program's terms exclude Medicare, Medicaid, TRICARE, VA and other government plans. UCB's Patient Assistance Program may supply Zilbrysq at no cost for up to 12 months to people who qualify financially. Our help paying page lists charity funds that may help.Cost and copay terms
Cigna prior authorization policy, May 1, 2026
- Age 18 or older, with generalized myasthenia gravis and a documented positive AChR antibody test
- Myasthenia Gravis Foundation of America class II to IV, and an MG-ADL score of 6 or more
- Has taken pyridostigmine, or it did not work, could not be used or was not tolerated
- Has taken 2 different immune-suppressing medicines for at least a year, or they did not work, could not be used or were not tolerated
- Symptoms that are still not under control, such as trouble swallowing or breathing
- Prescribed by or with a neurologist
- Not taken with another complement inhibitor, an FcRn blocker, rituximab or Uplizna
Approval length. Six months at first, then 1 year at a time if the prescriber says you are still benefiting.
This policy took effect in May 2026, before the October 2026 label added the autoinjector, and it cites the February 2025 label. The October change did not alter the dose or who Zilbrysq is for. The policy does not list the vaccines or the REMS, which the pharmacy checks separately. It counts a month as 30 days, while a pack lasts 28 days. It is here as an example of what a plan asks for, not as a rule. Cigna policy
Who to call, and what they can do
The drugmaker's program handles most of the first-fill problems above. Charity funds and foundation help are on the help paying page.
- A dedicated, medically trained Care Coordinator who calls after enrollment and helps with insurance and financial options
- Copay help for commercial insurance, as little as $0, not valid under Medicare, Medicaid, TRICARE, VA, DoD or other government plans Cost and copay terms
- The Patient Assistance Program, Zilbrysq at no cost for up to 12 months for people who meet its financial criteria Cost and copay terms
- Help getting the required vaccines through PANTHERx Rare, at a local pharmacy or at home, with a prescription from your neurologist Vaccination requirements
- A Welcome Kit with the first shipment and refresher injection coaching ONWARD treatment prep
- Symptom tracking tools and self-injection tips
Details as the drugmaker publishes them. UCB ONWARD
Five questions for the pharmacist or the support line
- Do you have my meningitis vaccine dates from my neurologist, and is anything still missing before you can ship?
- What number will PANTHERx Rare call me from to schedule each delivery?
- Is my dose set for my current weight, and what happens if my weight changes?
- When should I expect the refill call for my next 28-day pack?
- Can you arrange my meningitis vaccines or boosters at home or at a nearby pharmacy?
- Has my copay help been applied, and what will I pay for each pack?
Questions people ask in the first weeks
How long does it take to start Zilbrysq after it is prescribed?
The vaccines set the floor, at least 2 weeks between the meningitis shots and the first dose, unless the neurologist starts antibiotics instead. The pancreas blood test, the REMS checks and the insurance approval run alongside. None of the sources on this page gives a fixed number of days.
Which vaccines do I need before Zilbrysq?
Meningococcal vaccines against serogroups A, C, W, Y and B, at least 2 weeks before the first dose, on the ACIP schedule for complement inhibitors. The label also asks for pneumococcal vaccines on the ACIP schedule. Shots you had in the past may not be enough, and the neurologist decides.
Can I pick up Zilbrysq at my regular pharmacy?
No, only REMS-certified pharmacies can dispense it, and UCB says it is filled only through PANTHERx Rare, which ships to your home.
What if I miss a dose of Zilbrysq?
The label says to inject it as soon as possible, then go back to your usual time. It also says never to inject more than 1 dose in a day.
What is the Patient Safety Card?
A card from your neurologist that says you take Zilbrysq and lists the signs of meningococcal infection. The label requires carrying it at all times during treatment and for 2 months after the last dose. The Medication Guide says to show it to any provider who treats you.
Does Zilbrysq need blood tests?
The label asks for lipase and amylase before the first dose to check the pancreas. The label sets no repeating blood test schedule after that first check. Severe or lasting stomach pain is the sign to call about.
Is there a Zilbrysq autoinjector?
Yes, the FDA approved a once-daily autoinjector on October 15, 2026, at the same 3 doses. UCB said on October 16, 2026 that it expects the autoinjector to be available in the first quarter of 2027. Until it launches, the prefilled syringe remains the form that is available.
Is Zilbrysq approved if I do not have AChR antibodies?
No, the label covers only adults with generalized myasthenia gravis who test positive for AChR antibodies. The Cigna policy on this page also asks for a documented positive test.
Free email alert
Hear when the Zilbrysq label changes
One email the day the FDA revises the Zilbrysq label, with what changed in plain words. No trial alerts, no newsletter.
Label changes for Zilbrysq only, usually a few a year and some years none. Stop anytime. We never share your email. Privacy policy
Want the whole condition instead? Follow Generalized myasthenia gravis for new trials, FDA decisions and label changes for every treatment.
Sources
- ZILBRYSQ (zilucoplan) injection, for subcutaneous use, prescribing information, Medication Guide and Instructions for Use, revised October 2026, UCB, via Drugs@FDA, October 15, 2026.
- Approved Risk Evaluation and Mitigation Strategies (REMS), Zilbrysq (zilucoplan) NDA 216834, FDA, February 28, 2025.
- ZILBRYSQ REMS Patient Guide, what you need to know about ZILBRYSQ, UCB, via FDA REMS@FDA, February 28, 2025.
- ZILBRYSQ REMS Prescriber Enrollment Form, UCB, via FDA REMS@FDA, February 28, 2025.
- ONWARD and You (ZILBRYSQ) | UCB ONWARD, UCB, November 7, 2026.
- Insurance and ZILBRYSQ | UCB ONWARD, UCB, November 7, 2026.
- Treatment Prep | UCB ONWARD, UCB, November 7, 2026.
- Financial Support for ZILBRYSQ (zilucoplan) Injection, with the Copay Assistance Program terms and conditions, UCB, November 7, 2026.
- Vaccination Requirements for ZILBRYSQ, UCB, November 7, 2026.
- Start Form for ZILBRYSQ (zilucoplan) Injection For Subcutaneous Use, US-ZL-2600316, UCB, September 29, 2026.
- ZILBRYSQ (zilucoplan) Is Available Exclusively Through a Single Specialty Pharmacy, PANTHERx Rare, US-ZL-2500139, UCB, March 1, 2025.
- Drug Coverage Policy IP0622, Complement Inhibitors, Zilbrysq, Cigna, May 1, 2026.
- UCB announces U.S. FDA approval for ZILBRYSQ (zilucoplan) autoinjector self-administration for adults living with generalized myasthenia gravis, UCB, October 16, 2026.
- NDA 216834/S-015 approval letter, single-dose prefilled autoinjector, FDA, October 15, 2026.
- NDA 216834/S-013 approval letter, pregnancy exposure information contact, FDA, January 22, 2026.
- NDA 216834/S-008 and S-009 approval letter, meningococcal infection labeling and REMS modification, FDA, February 28, 2025.
- NDA 216834/S-001 approval letter, morphea added to postmarketing experience, FDA, April 26, 2024.
This page explains what the FDA label, the drugmaker's support program and an insurer policy say. It is not medical advice and does not tell anyone to start, stop or change a medicine. Dosing, test timing and restarts after a gap are decisions for the prescribing neurologist. Found an error? Use the report link in the footer and it will be checked against the source.